CHICAGO, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (OTCQX: COSM), international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established European Union distribution network, today provided a business update and reported financial results for the second quarter ended June 30, 2021.
Read the original:
Cosmos Holdings Reports 15.8% Year-Over-Year Growth and 27.8% Sequential Increase in Revenue for the Second Quarter of 2021
Related Post
- Skye Bioscience Appoints Kaitlyn Arsenault as Chief Financial Officer - October 5th, 2021
- Journey Medical Corporation Appoints Ernest De Paolantonio as Chief Financial Officer - October 5th, 2021
- Genovac Purchases Third Beacon® Optofluidic System and Expands its Capabilities into Cell Line Development - October 5th, 2021
- Albireo Recognizes PFIC Awareness Day 2021 - October 5th, 2021
- CohBar to Present at H.C. Wainwright 5th Annual NASH Investor Conference - October 5th, 2021
- Celsion Corporation Adds Key Resources to its Vaccine Development Initiative and Clinical Trial Capabilities - October 5th, 2021
- Scopus BioPharma to Present at the LD Micro Main Event - October 5th, 2021
- TCR² Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at AACR Virtual Special Conference on Tumor Immunology & Immunotherapy - October 5th, 2021
- AXIM® Biotechnologies Appoints Senior DED Expert Dr. Laura Periman to its Medical Advisory Board - October 5th, 2021
- Levitee Labs Publishes First Revenue Figures for August 2021 - October 5th, 2021
- SEngine Precision Medicine and Gustave Roussy Announce Plan to Launch PARIS® Test in Europe - October 5th, 2021
- Weblink Instructions for the Annual Meeting of Shareholders of Zivo Bioscience, Inc. - October 5th, 2021
- Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc. - October 5th, 2021
- Shockwave Medical to Report Third Quarter 2021 Financial Results on November 8, 2021 - October 5th, 2021
- CRISPR Therapeutics to Host Virtual Event Highlighting CTX110™ Clinical Data - October 5th, 2021
- Terns Pharmaceuticals to Present at H.C. Wainwright 5th Annual NASH Investor Conference - October 5th, 2021
- Oncternal Therapeutics Announced Pre-Clinical Data from ONCT-534, an Androgen Receptor N-Terminal-Domain-Binding Small Molecule Degrader, Was Accepted... - October 5th, 2021
- Neuronetics Announces Commercial Agreement with Success TMS - October 5th, 2021
- Eledon Pharmaceuticals Announces Upcoming Presentation on AT-1501 at the Virtual 2021 International Pancreas and Islet Transplantation Association... - October 5th, 2021
- Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week - October 5th, 2021
- Better Choice Company Board of Directors Authorize Stock Repurchase Program - August 18th, 2021
- Comment on news - August 18th, 2021
- Lixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine... - August 18th, 2021
- Greenrose Acquisition Corp. Increases Full Year 2022 Financial Outlook - August 18th, 2021
- 22nd Century to Present at SNN Network Investor Conference on August 19 - August 18th, 2021
- XcelPlus International inks letter of intent to build plasma gasifiers for India landfill removal consortium - August 18th, 2021
- Accelus Launches Ultra-Low-Profile FlareHawk7™ Expandable Cage Implant and Innovative Instruments to Support Endoscopic, MIS Lumbar Fusion... - August 18th, 2021
- Cue Biopharma Reports Second Quarter 2021 Results, Recent Data Updates of CUE-101 Phase 1 Dose Escalation and Expansion Study, Platform Progress and... - August 18th, 2021
- Zivo Bioscience, Inc. Issues Letter to Shareholders - August 18th, 2021
- Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency - August 18th, 2021
- Ascendis Pharma A/S Announces Second Quarter 2021 Financial Results and Business Update Conference Call on August 25 - August 18th, 2021
- FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors - August 18th, 2021
- ProMIS Neurosciences Inc. Announces US$15 Million Offering of Units - August 18th, 2021
- Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat Cancer - August 18th, 2021
- Chalice Brands Ltd. Announces Timing of Its Second Quarter Earnings Results - August 18th, 2021
- Telix and Merck KGaA, Darmstadt, Germany, to Commence Pan-Cancer Clinical Combination Studies - August 18th, 2021
- Telix and Merck to Commence Pan-Cancer Clinical Combination Studies - August 18th, 2021
- Two New Studies to Explore Telix Assets in Breast Cancer Theranostics - August 18th, 2021
- Albireo and Genpharm Announce Agreement to Commercialize Bylvay™ (odevixibat) in Saudi Arabia and the Gulf Region - August 18th, 2021
- Cassava Sciences to Present New Clinical Dataset at 2021 Alzheimer’s Association International Conference - July 22nd, 2021
- Vericel to Report Second-Quarter 2021 Financial Results on August 4, 2021 - July 22nd, 2021
- Ladenburg Thalmann to Host R&D; Showcase Featuring Artelo Biosciences’ CAReS Study on July 28, 2021 - July 22nd, 2021
- LEXEO Therapeutics Expands Cardiac Gene Therapy Pipeline with Acquisition of Stelios Therapeutics and its Gene Therapy Programs for Rare... - July 22nd, 2021
- Tauriga Sciences Inc. Commences Sales of its Tauri-Gum Product Line in the United Kingdom - July 22nd, 2021
- Nanopharm and Leyden Labs Announce Agreement to Develop Intranasal Spray Product Candidates for Prophylactic Use Against Known and New Respiratory... - July 22nd, 2021
- Berkeley Lights announces technology collaboration to accelerate and improve gene therapy viral vector development and manufacturing - July 22nd, 2021
- Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory Board - July 22nd, 2021
- Sorrento Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS, a Highly Potent Neutralizing Antibody Against SARS-CoV-2... - July 22nd, 2021
- Spectral Medical Inc. Announces $10 Million Offering - July 22nd, 2021
- Medolife Rx Schedules Investor Webcast for Tuesday, July 27, 2021 - July 22nd, 2021
- Sorrento Announces That Its Subsidiary Levena and Its Partner Escugen Have Received Clearance to Begin Clinical Trials With Anti-TROP-2 Antibody Drug... - July 22nd, 2021
- Collegium to Host Conference Call to Discuss Second Quarter 2021 Financial Results and Provide Corporate Update - July 22nd, 2021
- ERYTECH Confirms Plans To Submit BLA for Eryaspase in Hypersensitive ALL Patients - July 22nd, 2021
- Kane Biotech Announces Cancellation of Options and Issuance of Restricted Share Units - July 22nd, 2021
- Myriad Genetics Supports New ACMG Recommendation Statement on Increasing Access to Carrier Screening for All Ethnicities - July 22nd, 2021
- TRACON Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock - July 22nd, 2021
- TRACON Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $15.0 Million - July 22nd, 2021
- [Ad hoc announcement pursuant to Art. 53 LR] Roche reports good half-year results - July 22nd, 2021
- argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021 - July 22nd, 2021
- Y-mAbs Announces NMPA Submission of BLA for DANYELZA® (naxitamab-gqgk) in China - July 7th, 2021
- Praxis Precision Medicines to Present at Upcoming Investor Conferences - July 7th, 2021
- Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference - July 7th, 2021
- Amazon Brand Registry Approves the Application for the Company’s Flagship Brand: Tauri-Gum - July 7th, 2021
- Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology - July 7th, 2021
- CoImmune, Inc. Appoints Michael Fekete and Greg Tibbitts to its Board of Directors - July 7th, 2021
- Valneva Strengthens Management Team; Appoints Vincent Dequenne as SVP Operations and Joshua Drumm as VP Investor Relations - July 7th, 2021
- ZEALAND PHARMA A/S - TRANSACTIONS UNDER SHARE REPURCHASE PROGRAM - July 7th, 2021
- Monthly information related to total number of voting rights and shares composing the share capital – June 30, 2021 - July 7th, 2021
- Integrity Implants and Fusion Robotics Merge to Form Accelus - July 7th, 2021
- AIM ImmunoTech to Host Investor Update Webcast on Wednesday, July 14th at 11:00 AM ET - July 7th, 2021
- FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin (RTX) For Treatment of the Knee Pain in Osteoarthritis (OA) Patients - July 7th, 2021
- Kymera Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional... - July 7th, 2021
- Opiant Pharmaceuticals Announces Positive Top-line Results of Confirmatory Pharmacokinetic (PK) Study for OPNT003, Nasal Nalmefene, a Novel... - July 7th, 2021
- NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors - July 7th, 2021
- Auxly Strengthens Financial Position With the Implementation of Amendments to Imperial Brands $123 Million Convertible Debenture and Sale of Curative... - July 7th, 2021
- Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic Fibrosis - July 7th, 2021
- Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles - July 7th, 2021
- XBiotech Announces Dividend to Holders of Common Stock - July 7th, 2021
- Addex Therapeutics to Present at Access to Giving Virtual Conference on July 14, 2021 - July 7th, 2021
- Update – Nanox to Participate in the Jefferies Virtual Healthcare Conference - May 28th, 2021